Generated by AI
Mira Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapeutics for neurologic, neuropsychiatric, metabolic, and pain-related disorders. The company’s pipeline centers on investigational drug candidates such as Ketamir-2, MIRA-55, and SKNY-1, which are being evaluated for conditions including neuropathic and inflammatory pain, anxiety, cognitive impairment, obesity, addiction-related disorders, and smoking cessation. Mira Pharmaceuticals concentrates on early-stage drug discovery and development, with an emphasis on small-molecule therapies designed to address unmet medical needs across the central nervous system and related treatment areas. The company operates as a specialized developer within the pharmaceutical sector, with its current work centered on advancing experimental treatments rather than commercial products.
Website1200 Brickell Avenue
Miami, FL, 33131
United States
The latest articles about MIRA.
Summary of May 27's posts. Generated by AI.
Summary of May 17's posts. Generated by AI.
Summary of Sep 1's posts. Generated by AI.
Investors talking about MIRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.